Can computation validate the final scientific claim?

No. A clean assay result still requires biological and translational interpretation. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.

When should the project stop or reframe?

Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.

Drug Discovery

Assay Artifact Checks Before Believing a Discovery Signal

Published 2026-08-22 · Updated 2026-08-22

Answer in brief

Assay Artifact Checks Before Believing a Discovery Signal becomes decision-useful when the team states whether an apparent activity signal could be technical rather than biological, not when it collects another undirected summary. Use controls, interference, aggregation, plate effects, readout specificity, concentration response, and orthogonal assays to compare mechanisms and run this early falsifier: repeat with an orthogonal readout and interference controls. Continue only if the ranking survives.

Evidence status: Decision-method guide; not a completed investigation or final validation.

The decision this guide supports

whether an apparent activity signal could be technical rather than biological

Why the problem is difficult

The article-specific identification challenge is whether the question “whether an apparent activity signal could be technical rather than biological” can be resolved using controls, interference, aggregation, plate effects, readout specificity, concentration response, and orthogonal assays, rather than merely restated in new language.

A falsifier-first workflow

Define the decision precisely: whether an apparent activity signal could be technical rather than biological.
Build a source and data ledger around controls, interference, aggregation, plate effects, readout specificity, concentration response, and orthogonal assays.
Compare the inherited route with a mechanistically distinct alternative and a constraint-based null.
Actively search for the strongest counterevidence relevant to this decision, including boundary cases and prior failures.
Run the lowest-cost discriminating challenge: repeat with an orthogonal readout and interference controls.
Record pursue, reframe, or stop, the confidence level, the evidence ceiling, and who owns downstream validation.

Decision criteria

Decision impact: would the result materially change the choice about whether an apparent activity signal could be technical rather than biological?
Evidence fit: does the available evidence—controls, interference, aggregation, plate effects, readout specificity, concentration response, and orthogonal assays—directly address the decision rather than merely correlate with it?
Discrimination: does the preferred route predict an outcome a credible alternative does not?
Robustness: does the ranking survive the challenge “repeat with an orthogonal readout and interference controls”?
Validation boundary: is the conclusion no stronger than the available sources, data and computation?

Supporting evidence

controls, interference, aggregation, plate effects, readout specificity, concentration response, and orthogonal assays

Counterevidence

For this decision, a result from “repeat with an orthogonal readout and interference controls” that reverses or flattens the ranking must remain visible even when it is commercially inconvenient.

Computation

Here computation earns its place only if it changes the choice about whether an apparent activity signal could be technical rather than biological or exposes why the available evidence cannot resolve it.

Fastest falsifier

repeat with an orthogonal readout and interference controls

When to stop or reframe

A decision-specific stop trigger is failure of the challenge “repeat with an orthogonal readout and interference controls” without an independently supported alternative mechanism.

Evidence ceiling

A clean assay result still requires biological and translational interpretation.

Sources and starting points

Open Targets Platform — Integrated public evidence connecting therapeutic targets and diseases.
ChEMBL — Curated bioactivity information for compounds, assays, and targets.
ClinicalTrials.gov — Official registry and results database for clinical studies; registry records are not proof of efficacy.
PubMed — Primary biomedical literature discovery; individual studies require direct appraisal.
PubChem — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.
FDA Drug Development and Approval Process — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.

Continue the decision journey

Explore the full topic hub · Editorial standard · Scientific Oracle consulting

Frequently asked questions

What decision does “Assay Artifact Checks Before Believing a Discovery Signal” help make?: It supports a bounded decision about whether an apparent activity signal could be technical rather than biological. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.
What is the fastest useful test?: repeat with an orthogonal readout and interference controls
Can computation validate the final scientific claim?: No. A clean assay result still requires biological and translational interpretation. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.
When should the project stop or reframe?: Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.